Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun Pharma

The Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medication, Bevatas, to the market. This decision overturns a previous block on the drug, affirming the court's view that Bevatas and Sun Pharma's Bevetex are sufficiently different in their ingredients and intended use.